Abstract:Thyroid cancer has emerged as the most rapidly proliferating solid neoplasm. In this study, we included a cohort of patients who underwent sonographic assessment and surgical intervention at the Sir Run Run Shaw Hospital, associated with the School of Medicine at Zhejiang University, spanning from January 2019 to June 2020. Stratification of cases was based on a combination of preoperative ultrasonographic evaluations and postoperative histopathological diagnoses, resulting in three distinct groups: high-risk papillary thyroid carcinoma (PTC) labeled as C1, low-risk PTC designated as C2, and a control group (N) composed of benign thyroid tissue adjacent to the carcinoma. Proteomic and phosphoproteomic analyses were conducted on PTC specimens. The comparative assessment revealed that proteins up-regulated in the C1/N and C2/N groups were predominantly involved in functions such as amino acid binding, binding of phosphorylated compounds, and serine protease activity. Notably, proteins like NADH dehydrogenase, ATP synthase, oxidoreductases, and iron ion channels were significantly elevated in the C1 versus C2 comparative group. Through meticulous analysis of differential expression multiples, statistical significance, and involvement in metabolic pathways, this study identified eight potential biomarkers pertinent to PTC metastasis diagnostics, encompassing phosphorylated myosin 10, phosphorylated proline-directed protein kinase, leucine tRNA synthetase, 2-oxo-isovalerate dehydrogenase, succinic semialdehyde dehydrogenase, ADP/ATPtranslocase, pyruvate carboxylase, and fibrinogen. Therapeutic assays employing metformin, an AMP-activated protein kinase (AMPK) activator, alongside the phosphorylation-specific inhibitor ML-7 targeting Myosin10, demonstrated attenuated cellular proliferation, migration, and invasion capabilities in thyroid cancer cells, accompanied by a reduction in amino acid pools. Cellular colocalization and interaction studies elucidated that AMPK activation imposes an inhibitory influence on Myosin10 levels. The findings of this research corroborate the utility of proteomic and phosphoproteomic platforms in the identification of metastatic markers for PTC and suggest that modulation of AMPK activity, coupled with the inhibition of Myosin10 phosphorylation, may forge novel therapeutic avenues in the management of thyroid carcinoma. SIGNIFICANCE: The significance of our research lies in its potential to transform the current understanding and management of thyroid papillary carcinoma (PTC), particularly in its metastatic form. By integrating both proteomic and phosphoproteomic analyses, our study not only sheds light on the molecular alterations associated with PTC but also identifies eight novel biomarkers that could serve as indicators of metastatic potential.

Cyclin-dependent kinase 7 is a potential therapeutic target in papillary thyroid carcinoma.

Targeting CDK7 in oncology: The avenue forward.

Targeting Cyclin D1 As a Therapeutic Approach for Papillary Thyroid Carcinoma

The Involvement of CXCR7 in Modulating the Progression of Papillary Thyroid Carcinoma.

KLK7, KLK10, and KLK11 in Papillary Thyroid Cancer: Bioinformatic Analysis and Experimental Validation

Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression

USP7 promotes proliferation of papillary thyroid carcinoma cells through TBX3-mediated p57KIP2 repression

Recent advances in the development of cyclin-dependent kinase 7 inhibitors

Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma

CDK7 in Breast Cancer: Mechanisms of Action and Therapeutic Potential.

CDK5RAP3 Acts As a Putative Tumor Inhibitor in Papillary Thyroid Carcinoma Via Modulation of Akt/GSK-3β/Wnt/β-catenin Signaling.

MicroRNA-7 Inhibits Proliferation, Migration and Invasion of Thyroid Papillary Cancer Cells Via Targeting CKS2

Proteomic and Phosphoproteomic analysis of thyroid papillary carcinoma: Identification of potential biomarkers for metastasis

Recent Progress in Development of Cyclin-Dependent Kinase 7 Inhibitors for Cancer Therapy

LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway

Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma

Identification and Validation of Potential Target Genes in Papillary Thyroid Cancer.

CDK7 Inhibitor Suppresses Tumor Progression Through Blocking the Cell Cycle at the G2/M Phase and Inhibiting Transcriptional Activity in Cervical Cancer

Protein Tyrosine Kinase 7 (PTK7) in Breast Cancer: A Retrospective Analysis of Tumour Expression and Association with Clinical Outcome

Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.

Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview